Blog
RSS FeedPosted by Michael Wonder on 14 Nov 2023
ICER publishes evidence report on treatment for pulmonary arterial hypertension
14 November 2023 - Sotatercept added to background therapy appears to improve clinical outcomes, but there are uncertainties on long ...
Posted by Michael Wonder on 03 Nov 2023
ICER publishes third annual assessment of barriers to fair access within US commercial insurance prescription drug coverage
3 November 2023 - While many payers offer fair access across the domains evaluated, findings underscore the need for greater ...
Posted by Michael Wonder on 01 Nov 2023
ICER to assess MDMA assisted therapy for post-traumatic stress disorder
1 November 2023 - Report will be subject of New England CEPAC meeting in May 2024; draft scoping document open ...
Posted by Michael Wonder on 30 Oct 2023
ICER publishes final evidence report on gene therapy for metachromatic leukodystrophy
30 October 2023 - Independent appraisal committee voted that across all patient sub-populations, arsa-cel demonstrated a net health benefit when ...
Posted by Michael Wonder on 02 Oct 2023
ICER publishes special report on Eliquis and Xarelto submitted to CMS as part of public comment process on Medicare drug price negotiations
2 October 2023 - Report tailored to reflect legislative specifications in the Inflation Reduction Act and subsequent CMS guidance regarding ...
Posted by Michael Wonder on 27 Sep 2023
ICER appoints Daniel Ollendorf as Chief Scientific Officer and Director of HTA Methods and Engagement
27 September 2023 - Academic leader in HTA to rejoin ICER in November 2023. ...
Posted by Michael Wonder on 25 Sep 2023
ICER releases draft evidence report on treatment for pulmonary arterial hypertension
25 September 2023 - Registration now open for 5 October “Early Insights” webinar. ...
Posted by Michael Wonder on 25 Sep 2023
ICER finalises 2023 updates to value assessment framework
25 September 2023 - Updates to methods and public meeting procedures reflect experience with previous framework, benchmarking with other HTA groups, ...
Posted by Michael Wonder on 14 Sep 2023
ICER publishes evidence report on gene therapy for metachromatic leukodystrophy
14 September 2023 - Using weighted analyses across all patient subpopulations, atidarsagene autotemcel would achieve common thresholds for cost effectiveness if priced ...
Posted by Michael Wonder on 11 Sep 2023
An alternative measure of health for value assessment: the equal value life-year
10 September 2023 - The quality-adjusted life-year (QALY) is an international standard in cost-effectiveness analysis. A known concern arises from the ...
Posted by Michael Wonder on 21 Aug 2023
ICER publishes final evidence report on gene therapies for sickle cell disease
21 August 2023 - Current evidence suggests that lovo-cel and exa-cel would achieve common thresholds for cost-effectiveness if priced between $1.35 ...
Posted by Michael Wonder on 26 Jul 2023
ICER releases draft evidence report on treatment for metachromatic leukodystrophy
26 July 2023 - Registration now open for 3 August “Early Insights” webinar. ...
Posted by Michael Wonder on 25 Jul 2023
ICER to assess treatments for paroxysmal nocturnal haemoglobinuria
25 July 2023 - Report will be subject of CTAF meeting in February 2024; draft scoping document open to public ...
Posted by Michael Wonder on 13 Jul 2023
ICER publishes evidence report on gene therapies for sickle cell disease
13 July 2023 - In the short term, both lovo-cel and exa-cel can dramatically reduce the frequency of painful crises ...
Posted by Michael Wonder on 11 Jul 2023
ICER launches a patient council to amplify the patient voice in value assessment
11 July 2023 - Patient Council will advise ICER on engaging with patient groups while also identifying strategies to communicate ...